09/17/2026 02:00
Lattice Advances FPGA Design with New Leadership AI-Driven Development Tool, Lattice Prompt

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today introduced a new leadership AI-powered FPGA development tool for small and mid-range FPGAs that redefines how FPGA developers work across the full design flow. Lattice Prompt pairs with AI agentic tools developers already use, combining them with Lattice design tools, knowledge base, and documentation to turn natural language inputs into validated responses, dramatically accelerating FPGA develop...

09/17/2026 02:00
Lattice Expands Secure Control FPGA Leadership with New Lattice Mach-N2 Family

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced Lattice Mach™-N2 FPGA family, extending its long-running secure control FPGA leadership with new devices purpose-built for system control and security in modern infrastructure. Built on the Lattice Nexus™ 2 small FPGA platform, Mach-N2 combines integrated flash, a hardware Root of Trust, and CNSA 2.0-compliant post-quantum cryptography (PQC) with crypto agility for trusted, always-on sy...

The Audio Marketplace (TAM) Expands Its Audio Content Offering with AFP

The Audio Marketplace (TAM), a European platform dedicated to the distribution and monetisation of professional audio content, has expanded its offering with the addition of a daily news feed produced by AFP.

The Audio Marketplace (TAM), a European platform dedicated to the distribution and monetisation of professional audio content, has expanded its offering with the addition of a daily news feed produced by AFP.
Anglais
10/21/2026 10:47
Compvide Announces Commercial Launch of CIMED and Presents New Research at European Meeting on Complement in Human Disease (EMCHD) 2026

Compvide, Inc. today announced the commercial launch of its CIMED platform. The CIMED-AP, CIMED-LP, and CIMED-CP kits assess the alternative, lectin, and classical complement pathways, respectively, using 50% serum to support testing under more physiological conditions. The commercial launch follows Compvide’s participation in the 20th European Meeting on Complement in Human Disease (EMCHD), held September 1–5, 2026, in Cardiff, Wales. Through a scientific presentation, poster, and exhibition, t...